|
Title
|
Published
|
Price
|
By
CHI Healthtech
The present Competitive Intelligence Report about CMV Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, antisense, proteins, cells and small molecules against infection w...
|
August 2012
|
$
266
|
By
CHI Healthtech
Alzheimer’s disease is an extraordinarily active realm of research, with nearly 100 products in clinical development and many more at the discovery and preclinical stages. The competition in this arena is fierce, but the company that produce...
|
June 2012
|
$
595
|
By
CHI Healthtech
The present Competitive Intelligence Report about RSV Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, small molecules and RNAi against infection with respiratory syncyt...
|
June 2012
|
$
333
|
By
CHI Healthtech
This study - designed, executed and analyzed by research professionals from the drug development and commercialization industry - sheds light on prescribers' views of biosimilars. It is based on interviews with 264 physicians in the United Sta...
|
June 2012
|
$
750
|
By
CHI Healthtech
The present Competitive Intelligence Report about prophylaxis and therapy of S. aureus infections provides a competitor evaluation in the field of molecules for prevention or treatment of Staphylococcus aureus infections as of May 2012. Purchase o...
|
May 2012
|
$
399
|
By
CHI Healthtech
The present Competitive Intelligence Report about Pseudomonas aeruginosa Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, peptides and small molecules as well as DNA-, R...
|
May 2012
|
$
266
|
By
CHI Healthtech
The present Competitive Intelligence Report about new developments in the pipeline of inhibitors of the janus-associated kinase (JAK) provides a competitor evaluation in the field of active R&D projects from preclinical stages up to mark...
|
May 2012
|
$
394
|
By
CHI Healthtech
It was supposed to be the epoch of biosimilars, or drugs that copied existing biologics but had the potential to be more cost-effective. Yet five years later, biosimilars have failed to reach their forecasted potential of $16.4 billion...
|
January 2012
|
$
895
|
By
CHI Healthtech
Between now and 2019, a vast range of blockbuster drugs will go off patent, opening the floodgates in the EU to the biosimilars market. Already established there since 2006, biosimilars are set to be worth between $2.25 billion and $4.8 billion by...
|
November 2011
|
$
595
|
By
CHI Healthtech
The value of PR can seem immeasurable in brand positioning. Yet, in an age of budgetary juggling by marketing departments, the drive to scrutinize ROI is increasingly important. What' s more, as expectations on PR outcomes increase - in part d...
|
September 2011
|
$
495
|
By
CHI Healthtech
Marketing excellence. Over the past five years, those two words have been the subject of hype and the focus of management attention. As the pharmaceutical industry struggles with market maturation and weakening product pipelines, marketing excelle...
|
August 2011
|
$
595
|
By
CHI Healthtech
The field of kinase modulation is one of the most active in the biopharmaceutical industry. About 20 kinase inhibitors are approved for marketing in the United States and at least another 250 are in clinical evaluation. Kinases make up a veritable...
|
August 2011
|
$
595
|
By
CHI Healthtech
With the launch of Apple's iPad in April 2010, the way we use technology changed forever. Instant, portable and quick, the iPad is expected to sell 50 million units in 2011 alone.Its impact on Pharma is still being measured, but fo...
|
July 2011
|
$
295
|
By
CHI Healthtech
They’re costly to develop, fraught with potential patient safety concerns and subject to regulations that have yet to be written.Yet for the pharmaceutical industry, biosimilar monoclonal antibodies (mAbs) represent a potential treasu...
|
February 2011
|
$
395
|
By
CHI Healthtech
Worldwide, the story is the same. Governments want cheaper drugs for their populations, while the number and kinds of diseases affecting them continue to evolve and grow.Since 1976, when Genentech became the world’s first biopharmaceu...
|
October 2010
|
$
395
|